Literature DB >> 27256204

Comparison of Pathological Outcomes for Men with Low Risk Prostate Cancer from Diverse Practice Settings: Similar Results from Immediate Prostatectomy or Initial Surveillance with Delayed Prostatectomy.

Gregory B Auffenberg1, Susan Linsell1, Apoorv Dhir1, Stacie N Myers1, Bradley Rosenberg2, David C Miller3.   

Abstract

PURPOSE: We compared pathological outcomes after radical prostatectomy for a population based sample of men with low risk prostate cancer initially on active surveillance and undergoing delayed prostatectomy vs those treated with immediate surgery in order to better understand this expectant management approach outside of the context of academic cohorts. We hypothesized that delays in surgery due to initial surveillance would not impact surgical pathological outcomes.
MATERIALS AND METHODS: We performed a prospective cohort study of 2 groups of patients with NCCN low risk prostate cancer from practices in the Michigan Urological Surgery Improvement Collaborative, that is 1) men who chose initial active surveillance and went on to delayed prostatectomy and 2) men who chose immediate prostatectomy. Diagnoses occurred from January 2011 through August 2015. For these 2 groups we compared radical prostatectomy Gleason scores, and rates of extraprostatic disease, positive surgical margins, seminal vesicle invasion and lymph node metastases.
RESULTS: During a median followup of 506 days 79 (6%) of 1,359 low risk men choosing initial surveillance transitioned to prostatectomy. Compared to those treated with immediate prostatectomy (778), men undergoing delayed surgery were more likely to have Gleason score 7 or greater disease (69.2% vs 48.8%, respectively, p=0.004), but were no more likely to have positive margins, extraprostatic extension, seminal vesicle invasion or lymph node metastases.
CONCLUSIONS: Patients with low risk prostate cancer who enter active surveillance have higher grade disease at prostatectomy compared to those undergoing immediate surgery. However, the lack of difference in other adverse pathological outcomes suggests preservation of the window of curability.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  neoplasms; prostate; prostatic neoplasms; treatment outcome; watchful waiting

Mesh:

Year:  2016        PMID: 27256204      PMCID: PMC5069183          DOI: 10.1016/j.juro.2016.05.095

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

Authors:  Chenjie Zeng; Wanqing Wen; Alicia K Morgans; William Pao; Xiao-Ou Shu; Wei Zheng
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

Review 2.  Defining 'progression' and triggers for curative intervention during active surveillance.

Authors:  Laurence Klotz
Journal:  Curr Opin Urol       Date:  2015-05       Impact factor: 2.309

3.  Prostate cancer, version 2.2014.

Authors:  James L Mohler; Philip W Kantoff; Andrew J Armstrong; Robert R Bahnson; Michael Cohen; Anthony Victor D'Amico; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Christopher J Kane; Mark H Kawachi; Michael Kuettel; Timothy M Kuzel; Richard J Lee; Arnold W Malcolm; David Miller; Elizabeth R Plimack; Julio M Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Eric Rohren; Stan Rosenfeld; Edward Schaeffer; Eric J Small; Guru Sonpavde; Sandy Srinivas; Cy Stein; Seth A Strope; Jonathan Tward; Dorothy A Shead; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2014-05       Impact factor: 11.908

Review 4.  Active surveillance for low-risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

Review 5.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

6.  Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Authors:  Lisa F Newcomb; Ian M Thompson; Hilary D Boyer; James D Brooks; Peter R Carroll; Matthew R Cooperberg; Atreya Dash; William J Ellis; Ladan Fazli; Ziding Feng; Martin E Gleave; Priya Kunju; Raymond S Lance; Jesse K McKenney; Maxwell V Meng; Marlo M Nicolas; Martin G Sanda; Jeffry Simko; Alan So; Maria S Tretiakova; Dean A Troyer; Lawrence D True; Funda Vakar-Lopez; Jeff Virgin; Andrew A Wagner; John T Wei; Yingye Zheng; Peter S Nelson; Daniel W Lin
Journal:  J Urol       Date:  2015-08-29       Impact factor: 7.450

7.  Infection related hospitalizations after prostate biopsy in a statewide quality improvement collaborative.

Authors:  Paul R Womble; Maxwell W Dixon; Susan M Linsell; Zaojun Ye; James E Montie; Brian R Lane; David C Miller; Frank N Burks
Journal:  J Urol       Date:  2013-12-15       Impact factor: 7.450

8.  Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer.

Authors:  Pauline Filippou; Christopher J Welty; Janet E Cowan; Nannette Perez; Katsuto Shinohara; Peter R Carroll
Journal:  Eur Urol       Date:  2015-06-29       Impact factor: 20.096

9.  Applying precision medicine to the active surveillance of prostate cancer.

Authors:  Chad A Reichard; Andrew J Stephenson; Eric A Klein
Journal:  Cancer       Date:  2015-07-06       Impact factor: 6.860

10.  Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity.

Authors:  Marshall Godwin; Lucia Ruhland; Ian Casson; Susan MacDonald; Dianne Delva; Richard Birtwhistle; Miu Lam; Rachelle Seguin
Journal:  BMC Med Res Methodol       Date:  2003-12-22       Impact factor: 4.615

View more
  3 in total

1.  Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study.

Authors:  Shivanshu Awasthi; Travis Gerke; Jong Y Park; Francis A Asamoah; Vonetta L Williams; Angelina K Fink; Rajesh Balkrishnan; David I Lee; S Bruce Malkowicz; Priti Lal; Jasreman Dhillon; Julio M Pow-Sang; Timothy R Rebbeck; Kosj Yamoah
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-11-09       Impact factor: 4.254

2.  18F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management.

Authors:  Harikrishna Kommidi; Hua Guo; Fuad Nurili; Yogindra Vedvyas; Moonsoo M Jin; Timothy D McClure; Behfar Ehdaie; Haluk B Sayman; Oguz Akin; Omer Aras; Richard Ting
Journal:  J Med Chem       Date:  2018-04-20       Impact factor: 7.446

3.  Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 years.

Authors:  Brayden March; George Koufogiannis; Mark Louie-Johnsun
Journal:  Prostate Int       Date:  2017-04-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.